FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
Surgeons at Delray Medical Center have published early clinical experience with SMART, a scaffold-based reconstructive technique designed for selected complete muscle transection injuries where suturing alone may be mechanically unreliable. Published in PRS Global Open, the report describes six cases with no construct failures or wound complications reported during available follow-up.